Literature DB >> 9597402

Anticoagulation for cardioversion of atrial arrhythmias.

J Mayet1, R S More, G C Sutton.   

Abstract

We would advocate 3 weeks of anticoagulation prior to, and 4 weeks post-cardioversion (either electrical or chemical) for patients in chronic atrial fibrillation or flutter. In selected cases it seems reasonable to use transoesophageal echocardiography to exclude preformed thrombus and negate the need for 3 weeks of prior anticoagulation. For patients presenting acutely with atrial fibrillation or flutter we suggest anticoagulating with heparin immediately on presentation and for those who do not spontaneously revert to sinus rhythm, using transoesophageal echocardiography to exclude atrial thrombi prior to cardioversion. Oral anticoagulation should be continued for 4 weeks post-procedure. If transoesophageal echocardiography is not readily available an alternative strategy would be to anticoagulate the patient for 3 weeks and thereafter readmit them for elective cardioversion, continuing the anticoagulation for a further 4 weeks after the procedure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9597402     DOI: 10.1053/euhj.1997.0509

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  4 in total

1.  Managing atrial fibrillation in elderly people. What should target international normalised ratio be?

Authors:  T Lancaster
Journal:  BMJ       Date:  1999-08-14

2.  Doppler tissue imaging for assessing left ventricular diastolic dysfunction in heart transplant rejection.

Authors:  S M Stengel; Y Allemann; M Zimmerli; E Lipp; N Kucher; P Mohacsi; C Seiler
Journal:  Heart       Date:  2001-10       Impact factor: 5.994

3.  Pulmonary venous flow velocity patterns in 404 individuals without cardiovascular disease.

Authors:  S F de Marchi; M Bodenmüller; D L Lai; C Seiler
Journal:  Heart       Date:  2001-01       Impact factor: 5.994

Review 4.  Cost effectiveness of therapies for atrial fibrillation. A review.

Authors:  M P Teng; L E Catherwood; D P Melby
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.